STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy
ConditionImmune Checkpoint Therapy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorM.D. Anderson Cancer Center
About this trial
To learn if monitoring blood levels of heart injury (troponin levels) in cancer participants treated with immune checkpoint inhibitors will lead to decreased heart-related side effects.
Eligibility criteria
Qualifiers
Male or female patient ≥18 years old
Plan for treatment with an immune checkpoint inhibitor as standard of care even if patient is also on an additional investigational cancer therapeutic
Willingness to provide informed consent
Disqualifiers
Troponin T not available at screening or prior to randomization
Inability to comply with planned study procedures
Major adverse cardiovascular event included in the primary outcome within the 30 days prior to enrollment
Any medical condition that could interfere with, or for which the treatment might interfere with the conduct of the study or interpretation of the study results, or that would, in the opinion of the investigator, increase the risk of the participant by participating in the study
Trial design
Treatments tested in this trial
- Troponin surveillance
- Standard of care
Treatment groups
980 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov